Logo

Top 20 BioPharma Companies based on 2021 Total Revenue

Share this
Top 20 BioPharma Companies based on 2021 Total Revenue

Top 20 BioPharma Companies based on 2021 Total Revenue

  • While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfolios
  • While top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also entered the list and, with massive growth in their revenue
  • J&J remains at the top with a revenue of $93.80B, followed by Pfizer & Roche with $81.30B & $69.84B, respectively. PharmaShots has compiled a list of the top 20 biopharma companies based on their 2021 total revenue

Total Revenue: $17.89B

Pharma Segment Revenue: $17.89B

Founded Year: 2019

Market Cap: $13.29B

Total Employees: ~40,000

Non-Pharma Segment Revenue: Nil

Headquarters: Canonsburg, United States

Stock Exchange: NASDAQ

Viatris is a global healthcare company formed by the merger of Mylan and Upjohn (generics division of Pfizer) that deals with generics, biosimilars, and over-the-counter products. Viatris' 2021 revenue shoots up to 50% vs. 2020. In Nov 2021, Viatris, with Biocon, launched biosimilar Insulin Glargine - Semglee for Type 1 Diabetes.

Total Revenue: $18.47B

Pharma Segment Revenue: $18.47B

Founded Year: 2010

Market Cap: $68.38B

Total Employees: ~1300

Non-Pharma Segment Revenue: Nil

Headquarters: Massachusetts, United States

Stock Exchange: NASDAQ

Moderna is an American Biopharma company focused on RNA therapeutics and developing mRNA vaccines. Moderna's 2021 revenue rocket to 2,200% vs 2020. In 2021, Moderna entered into multiple agreements and deals for its COVID-19 vaccine.

Total Revenue: $21.53B

Pharma Segment Revenue: $21.53B

Founded Year: 1923

Market Cap: $210.04B

Total Employees: ~48,478

Non-Pharma Segment Revenue: Nil

Headquarters: Bagsvaerd, Denmark

Stock Exchange: Copenhagen

Novo Nordisk is a global healthcare company, a leader in diabetes and obesity care. Novo Nordisk's 2021 revenue grew to 11 % vs. 2020. In 2021, Novo Nordisk had two significant acquisitions. Its largest investment was in Dec 2021, when it acquired Dicerna Pharmaceuticals for $3.3B, and then in July 2021, it purchased Prothena's ATTR amyloidosis business for $1.2B.

Total Revenue: $21.58B

Pharma Segment Revenue: $21.58B

Founded Year: 2008

Market Cap: $44.27B

Total Employees: ~1941

Non-Pharma Segment Revenue: Nil

Headquarters: Mainz, Germany

Stock Exchange: NASDAQ

BioNTech is a German biotechnology company that develops next-generation immunotherapies for cancer and other serious diseases. BioNTech's 2021 revenue soared to 3834.6% vs. 2020. In Nov 2021, Pfizer and BioNTech's Comirnaty received CHMP's positive opinion for the treatment of COVID-19 in children aged 5 to 12 years.

Total Revenue: $22.39B

Pharma Segment Revenue: $8.06B

Founded Year: 1668

Market Cap: $26.64B

Total Employees: ~60,348

Non-Pharma Segment Revenue: $15.4B

Headquarters: Darmstadt, Germany

Stock Exchange: ETR

The Merck Group (Merck KGaA) is a German multinational science and technology company focused on oncology- immuno-oncology- and neurology & immunology. Merck KGaA's 2021 revenue increased by 12.3% vs. 2020. In Mar 2021, Merck KGaA signed an exclusive worldwide license agreement with Debiopharm for Xevinapant

Total Revenue: $25.97B

Pharma Segment Revenue: $25.97B

Founded Year: 1980

Market Cap: $135.32B

Total Employees: ~24,200

Non-Pharma Segment Revenue: Nil

Headquarters: California, United States

Stock Exchange: NASDAQ

Amgen is an American Biopharma company headquartered in Thousand Oaks, California. Amgen's 2021 revenue increased by 2% vs. 2020. In Oct 2021, Amgen completed its acquisition of Teneobio for ~$2.5B. In addition, in Dec 2021, Janssen and Amgen's Darzalex Faspro (daratumumab and hyaluronidase-fihj) received the US FDA's approval to treat multiple myeloma.

Total Revenue: $27.30B

Pharma Segment Revenue: $27.3B

Founded Year: 1987

Market Cap: $77.93B

Total Employees: ~60,348

Non-Pharma Segment Revenue: Nil

Headquarters: California, United States

Stock Exchange: NASDAQ

Gilead Sciences is a research-based biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines. Gilead's 2021 revenue increased by 11% vs. 2020. In Mar 2021, Gilead collaborated with Merck to jointly develop and commercialize Lenacapavir + Islatravir for HIV and received Epclusa (Sofosbuvir/Velpatasvir) approval from the US FDA for children with chronic hepatitis C infection in Jun 2022.

Total Revenue: $28.31B

Pharma Segment Revenue: $28.31B

Founded Year: 1876

Market Cap: $288.25B

Total Employees: ~35,238

Non-Pharma Segment Revenue: Nil

Headquarters: Indiana, United States

Stock Exchange: NYSE

Eli Lilly is an American pharma company that focuses on developing, manufacturing, and marketing human pharmaceutical products. Lilly's total revenue increased by 15% in 2021. Lilly's Verzenio (abemaciclib) received the US FDA's approval for people with HR+ HER2- high-risk early breast cancer in Oct 2021 and collaborated with Kumquat Biosciences to discover and develop novel small molecules that stimulate tumor-specific immune responses in July 2021.

Total Revenue: $37.41B

Pharma Segment Revenue: $37.41B

Founded Year: 1999

Market Cap: $211.65B

Total Employees: ~76,100

Non-Pharma Segment Revenue: Nil

Headquarters: Cambridge, United Kingdom

Stock Exchange: LON

AstraZeneca is a global pharmaceutical focusing on Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology. AstraZeneca's total revenue increased by 41% vs. 2020. In 2021, AstraZeneca launched 13 blockbuster drugs and collaborated with Ionis to develop and commercialize Eplontersen to treat transthyretin amyloidosis. In addition, the company witnessed 22 regulatory approval and authorizations in significant markets.

Total Revenue: $42.95B

Pharma Segment Revenue: $42.95B

Founded Year: 1973

Market Cap: $141.35B

Total Employees: ~95,442

Non-Pharma Segment Revenue: Nil

Headquarters: Paris, France

Stock Exchange: EPA

Sanofi is a global healthcare leader in vaccines providing healthcare solutions in 170+ countries worldwide. Sanofi's 2021 revenue increased 4.8% vs. 2020 revenue. In Sep 2021, Sanofi acquired Kadmon for ~$1.9B, which included transplant business with the addition of Kadmon's Rezurock to treat patients with cGVHD. The company has also acquired Translate Bio for ~$3.2B to utilize mRNA technology which accelerated Sanofi's licensed programs to develop transformative therapies & vaccines in Aug 2021.

Total Revenue: $43.07B

Pharma Segment Revenue: $4.71B

Founded Year: 1888

Market Cap: $210.70B

Total Employees: ~1,13,000

Non-Pharma Segment Revenue: 38.36

Headquarters: Illinois- United States

Stock Exchange: NYSE

Abbott Laboratories is an American multinational medical devices and healthcare company with four segments: Established Pharmaceutical and Nutritional Products, Diagnostics, and Medical Devices. Abbott's 2021 revenue showed an increase of 24.5% vs. 2020. Abbott's Amplatzer Amulet device received the US FDA's approval for the treatment of atrial fibrillation in Aug 2021.

Total Revenue: $46.17B

Pharma Segment Revenue: $46.17B

Founded Year: 1873

Market Cap: $118.23B

Total Employees: ~90,096

Non-Pharma Segment Revenue: Nil

Headquarters: Brentford, United Kingdom

Stock Exchange: LON

GSK is a global healthcare company focused on prescription medicines, vaccines & consumer healthcare products and is a leader in the areas of respiratory and HIV. GSK's 2021 increased by 5% as compared to 2020 revenue. In Jun 2021, GSK collaborated with iTeos to develop and commercialize EOS-448 for patients with cancer.

Total Revenue: $46.38B

Pharma Segment Revenue: $46.38B

Founded Year: 1887

Market Cap: $163.36B

Total Employees: ~32,200

Non-Pharma Segment Revenue: Nil

Headquarters: New York, United States

Stock Exchange: NYSE

Bristol-Myers Squibb (BMS) is an American pharmaceutical company focused on oncology, cardiovascular, and immunology. BMS's 2021 revenue increased by 9% vs. 2020. In Dec 2021, BMS' Orencia (abatacept) received the US FDA's approval to prevent acute graft versus host disease. In Jun 2021, it collaborated with Eisai for the development & co-commercialization of MORAb-202.

Total Revenue: $48.70B

Pharma Segment Revenue: $42.75B

Founded Year: 1891

Market Cap: $217.77B

Total Employees: ~68,000

Non-Pharma Segment Revenue: $ 5.95B

Headquarters: New Jersey, United States

Stock Exchange: NYSE

Merck & Co. is a global healthcare company focused on innovative health solutions by prescription medicines, vaccines, biological therapies, and animal health products. Merck & Co.'s 2021 revenue increased by 17% vs. 2020. In Sep 2021, Merck acquired Acceleron for $11.5B, strengthening its cardiovascular pipeline.

Total Revenue: $50.14B

Pharma Segment Revenue: $26.89B

Founded Year: 1863

Market Cap: $72.04B

Total Employees: ~99,637

Non-Pharma Segment Revenue: $22.99B

Headquarters: New Jersey, United States

Stock Exchange: ETR

Bayer is a global life science and healthcare company with three divisions- pharmaceuticals, consumer health, and crop science. Bayer's 2021 revenue increased by 6.5 % vs. 2020. In Aug 2021, Bayer acquired Vividion for ~$2B, which strengthened its drug discovery capabilities & expanded it into new modalities

Total Revenue: $51.62

Pharma Segment Revenue: $51.62

Founded Year: 1996

Market Cap: $226.14B

Total Employees: ~10,800

Non-Pharma Segment Revenue: Nil

Headquarters: Basel, Switzerland

Stock Exchange: Six Swiss Exchange-NYSE

Novartis is a multinational biopharma company focused on research, development, manufacturing, and marketing of a range of healthcare solutions, including generic and ophthalmic therapies. Novartis' 2021 revenue showed an increase of 8 % vs. 2020. In Dec 2021, Novartis strengthened its immunotherapy pipeline by collaborating with BeiGene for the TIGIT inhibitor, Ociperlimab

Total Revenue: $56.19

Pharma Segment Revenue: $56.19

Founded Year: 2013

Market Cap: $280.75B

Total Employees: ~50,000

Non-Pharma Segment Revenue: Nil

Headquarter: Illinois, United States

Stock Exchange: NYSE

AbbVie is a research-based global Biopharma company focused on developing therapies for chronic autoimmune diseases, oncology, and virology, with additional targets like cystic fibrosis and women's health. It has an enriched pipeline in immunology and neuroscience. AbbVie's 2021 revenue increased by 23 % vs. 2020. In Sep 2021, AbbVie collaborated with Regenxbio to develop and commercialize RGX-314 to treat retinal diseases.

Total Revenue: $69.84

Pharma Segment Revenue: $49.39

Founded Year: 1894

Market Cap: $341.52B

Total Employees: ~1,00,920

Non-Pharma Segment Revenue: $20.45

Headquarters: Basel, Switzerland

Stock Exchange: Six Swiss Exchange

Roche is a Swiss multinational healthcare company focused on pharmaceuticals and diagnostics divisions. Roche's 2021 increased by 9 % vs. 2020. In Aug 2021, Roche collaborated with Shape Therapeutics to develop gene therapies for Alzheimer's, Parkinson's, and rare diseases.

Total Revenue: $81.3

Pharma Segment Revenue: $81.3

Founded Year: 1849

Market Cap: $299.90B

Total Employees: ~1,21,831

Non-Pharma Segment Revenue: Nil

Headquarters: New York, United States

Stock Exchange: NYSE

Pfizer is a research-based global Biopharma company. In Apr 2020, it collaborated with BioNTech to develop, manufacture, and commercialize an mRNA-based coronavirus vaccine program, BNT162, to prevent COVID-19. Pfizer's 2021 revenue increased by 95.16 % vs.2020. In Dec 2021, Pfizer acquired Arena for ~ $6.7B and Trillium for ~$2.26B in Aug 2021.

Total Revenue: $93.8

Pharma Segment Revenue: $66.7

Founded Year: 1886

Market Cap: $475.07B

Total Employees: ~1,41,700

Non-Pharma Segment Revenue: $27.1

Headquarters: New Jersey, United States

Stock Exchange: NYSE

Johnson & Johnson (J&J) is an American multinational healthcare company focused on developing and commercializing pharmaceuticals, medical devices, and consumer packaged products. J&J's 2021 revenue increased by 13.6 % vs. 2020. In Nov 2021, the company planned to spin off its consumer health division to serve patients and consumers & unlocked value through the intent to separate the consumer health business.

$: All revenues are reported in USD.

Sources:

  • Annual reports,
  • SEC filings,
  • Press releases,
  • Company websites

Market Cap Source: Google finance (as of 13 April 2022)

Note: Takeda & Boehringer Ingelheim is not included in the top 20 list, as its actual revenue was not available. The data is collected as of 13 April 2022.

 

Related Post: Top 20 BioPharma Companies based on 2020 Total Revenue


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions